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Abstract: 
Cancer in a global threat as it is considered the primary cause of death worldwide. Breast cancer is the most common 
cancer I female worldwide. In the present study we evaluated the role of temozolomide, carboplatin, sodium 
phenylbutyrate, and cyclophosphamide in changing the methylation landscape of four tumor cell liness; breast, 
colorectal, lung, and cervical. Cells were treated with 5 µM of each drug and the cells were incubated with the drugs 
for 48 and 96 h before reading the changes in methylation patterns. Global methylation quantification was measured 
in cells after being treated with the drugs. Data obtained indicated that sodium phenylbutyrate, followed by 
temozolomide were the drugs most efficient in hypermethylation of the DNA, while carboplatin followed by 
cyclophosphamide were able to reduce the concentration of 5-mC in the DNA. It has been concluded that using 
carboplatin in combination with sodium phenylbutyrate (PBA) might induce cell cycle arrest of malignant cells. 
Further studies are needed to highlight the mechanism of action of these drugs when combined in treatment of cancer. 
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INTRODUCTION: 
Cancer is a group of diseases characterized by the uncontrolled 
growth and spread of abnormal cells [1], although the 
molecular basis underlying the disease remain unknown for 
many cancers [2]. There are many known cancer causes, 
including lifestyle factors, such as tobacco use and excess 
body weight [3], and non-modifiable factors, such as inherited 
genetic mutations [4] and epigenetic mutations such as 
hypermethylation of tumor suppressor genes, histone 
modifications, and miRNA dysregulation [5]. 
 
Breast cancer (BC) is the most common cancer and the leading 
cause of cancer deaths in females worldwide. Annually, about 
1.38 million new cases of BC are recognized, of which about 
35% females die [6]. Colorectal cancer (CRC) is a third most 
common epithelial carcinoma. CRC is known to develop from 
the early precancerous lesion to full-blown malignancy via 
definite phases due to cumulative mutations and aberrant 
methylation of number of genes [7].  CRC is a multifactorial 
disease that arises due to the cumulative accumulation of 
genetic as well as epigenetic alterations in a number of tumor 
suppressor [8]. 
 
Cervical cancer accounts for almost 12% of all cancers in 
women, representing the second most frequent gynecological 
malignancy and the major cause of deaths in women 
worldwide  [9]. It is difficult to foresee a dramatic increase in 
cure rate even with the most optimal combination of cytotoxic 
drugs, surgery, and radiation; therefore, testing of molecular 
targeted therapies against this malignancy is highly desirable 
[10-12]. Lung cancer is the leading cause of cancer death 
among men and women [13, 14]. Epigenetic alterations, 
including DNA methylation, histone modifications, and 
changes in non-coding RNA expression levels, widely 
reported in the literature, have been determined to play a major 
role in the genesis of lung cancer [15, 16].  
 
Epigenetic therapy is a novel tumor therapeutic method and 
refers to targeting of the aberrant epigenetic modifications 
presumably at cancer-related genes by chemicals, which are 
epigenetic targeting drugs [17-19]. As a cytotoxic alkylating 
agent, Temozolomide is converted at physiologic pH to the 
short-lived active compound, monomethyl triazeno imidazole 
carboxamide (MTIC).  
 
The cytotoxicity of MTIC is primarily due to methylation of 
DNA at the O6 and N7 positions of guanine, resulting in 
inhibition of DNA replication in ovarian, lung, head and neck, 
brain cancer, and neuroblastoma. Alkylating agents, like 
carboplatin, substitute alkyl groups for hydrogen atoms on 
DNA, resulting in the formation of cross links within the DNA 
chain and thereby resulting in cytotoxic, mutagenic, and 
carcinogenic effects [20-23]. Cyclophosphamide is an anti-
cancer chemotherapy drug. It belongs to a group of drugs 
called alkylating agents. It works by sticking to one of the 
DNA strands and thus hindering cell replication. Cancer cells 
are among the most affected because they are among the most 
rapidly dividing cells, however other rapidly dividing but 
normal cells like hematopoietic cells, intestinal mucosa, hair 
follicle , reproductive cells and endothelial cells are also 
affected by the drug [24-27]. 
Sodium phenylbutyrate (PBA) is a histone deacetylase 
inhibitor that possesses a broad spectrum of molecular 
functions. The compound can modulate the structure of 
chromatin and contributes to the regulation of cell cycle and 
apoptosis-related genes [28-32]. 
 
The present study aimed at evaluating the role of four 
chemotherapeutic epigenetic drugs on modulating the 
methylome of different cancer cell lines. 
 
MATERIALS AND METHODS: 
Cell line maintenance 
Breast adenocarcinoma cell line (MCF-7), colorectal cancer 
cell line (CaCo-2), cervical cancer cell line (HeLa), and lung 
cancer cell line (A549) were purchased from the Holding 
Company for Vaccines and Biological Products (VACSERA), 
Cairo, Egypt. Cells were cultured in RPMI 1640 media, 
supplemented with 10% v/v FBS and 1% 
antibacterial/antimycotic mix (penicillin, streptomycin, 
Amphotericin B) in humidified conditions with 5% CO2 at 
37°C. 
 
Chemotherapeutic drugs 
Four chemotherapeutic/epigenetic drugs: sodium 
phenylbutyrate, cyclophosphamide, carboplatin, and 
temozolomide were purchased from Santa Cruz 
Biotechnology (USA). 
 
Drug preparation and doses 
Different concentrations of the drugs were prepared, and 
combinations including sodium phenylbutyrate with other 
drugs were also prepared. After several trials, the final 
concentration of 5μM was chosen to treat cells for two 
incubation periods (48 and 96 h.).  
 
DNA extraction 
Genomic DNA was extracted from untreated (control) and 
treated cancer cells using DNA extraction kit (Cell Biolabs, 
USA) following the kit’s instructions. 
 
Global methylation quantification 
After being extracted, DNA was subjected to mechanical 
sheering (by vigorous vortexing for up to 10 min) before 
quantifying the global methylation status using MethylFlash 
methylation quantification kit (Cell Biolabs, USA). Briefly, 
samples were incubated at 95°C for 5 min and then chilled 
immediately on ice. The cooled samples were then treated with 
S1 nuclease followed by alkaline phosphatase for further 
enzymatic sheering of the DNA molecules. Anti 5-
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Methylcytidine antibody was added to the samples and 
incubated for 2 h at room temperature. Secondary anti-
conjugate antibody was added, and the samples were left for 
60 min. After that time substrate solution was added to the 
reaction mixture followed by the addition of stop solution. The 
plates were then read by a plate reader at 450 nm. 
 
Cell viability assay 
The dye exclusion test is used to determine the number of 
viable cells present in a cell suspension. It is based on the 
principle that live cells possess intact cell membranes that 
exclude trypan blue dye whereas dead cells do not. The test 
was performed before and after treatment [33].  
 
MTT assay 
The MTT assay is a colorimetric assay used for assessing cell 
metabolic activity. NAD(P)H-dependent cellular 
oxidoreductase enzymes may, under defined conditions, 
reflect the number of viable cells present. These enzymes are 
capable of reducing the tetrazolium dye MTT 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to its 
insoluble formazan, which has a purple color [34]. 
 
Statistical analysis 
Statistical analyses were performed by the SPSS 25 software 
package (SPSS, Inc, Chicago, IL). All values were expressed 
as mean ±SD. Analysis of variance with t test and analysis of 
variance (ANOVA) test were used to determine the 
significance of the difference in a multiple comparison. If the 
ANOVA was significant, the Tukey's procedure was used as a 
post hoc test. Differences with a P value of less than 0.05 were 
considered statistically significant. 
 
RESULTS: 
Cell count 
In the present study, cells were treated with different 
chemotherapeutic drugs for two incubation periods (48 and 96 
h.). Cell count was performed before and after treatment as an 
indicator on the cytotoxic effect of the drugs. Results are 
shown in Figure 1, Figure 2, and Table 1.  
 
Results indicated that for MCF-7 breast cancer cells, the most 
efficient treatment was S as it severely affected the overall cell 
count in the 48-h incubation period. The same was obtained in 
the 96-h incubation period. For colorectal cancer cells (Caco-
2), S also was the drug that negatively affected cell 
proliferation in the 48-h incubation period, while in the 96-h 
incubation period, C was the most efficient drug in reducing 
the cell count compared to control.  
 
For lung cancer cells (A549), C was the drug that affected cell 
growth in a severe manner in the short incubation period, while 
T has affected the cells in the long incubation period. For HeLa 
cervical cancer cells, T affected the cell proliferation severely 
in the 48-hours incubation period, while in the 96-hours 
incubation period, a different profile was obtained. Data 
obtained showed no significant differences between the two 
incubtaion periods of all treatments in all cells. 
 
 
 
 
 
 
   
Group Statistics 
Cell 
lines/Incubation 
period 
N Mean Std. Deviation t p 
MCF7 T1 15 25667.581 48691.910 0.142 0.888 
T2 15 23334.250 40998.860 
CaCo2 T1 15 25667.579 41741.236 0.754 0.457 
T2 15 16000.910 26872.135 
A549 T1 15 18000.913 35596.455 0.268 0.791 
T2 15 15000.909 24712.043 
HeLa T1 15 45000.916 81129.862  
1.536  
0.136 
T2 15 12000.912 18496.470 
Table (1): Statistical significance/non-significance between the two 
umcubation periods. 
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Figure 1: Viable cells counting by trypan blue test after treating the malignant cells with different types of 
chemotherapeutic drugs for 48 h. A: breast cancer cells, B: colon cancer, C cells lung cancer cells, and D: cervical 
cancer cells. CY: Cyclophosphamide, C: carboplatin, S: Sodium phenylbutyrate, and T: Temozolomide. ns: Non-
significant differences, *: significant, and **: very significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Viable cells counting by trypan blue test after treating the malignant cells with different types of 
chemotherapeutic drugs for 96 h. A: breast cancer cells, B: colon cancer, C cells lung cancer cells, and D: cervical 
cancer cells. CY: Cyclophosphamide, C: carboplatin, S: Sodium phenylbutyrate, and T: Temozolomide. ns: Non-
significant differences, *: significant, and **: very significant.  
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Cell viability assay 
MTT assay was performed to assess the cellular viability after 
treatement with different types of chemotherapetuic drugs. 
Results (figure 4 and 5) indicated that S has resulted in lowerd 
cell viability in breast cancer cells, colorectal cancer cells, and 
lung cancer cells. Cervical cancer cells gave a distictive profile 
where T has resulted in lowering the cell viability compared to 
control. These profiles were obtained in the 48-hours 
incubation period. In the long incubation period, all treatments 
have cuase the cell proliferation to increase compared to 
control.  
 
Global methylation quantification  
Global DNA methylation was quantified in cells after being 
treated with chemotherapeutic/epigenetics drugs. Results 
(figure 6 and 7) indicated that in the 48-h incubation period, 
breast cancer cells C has resulted in an increase in global DNA 
methylation, compared to control. In colorectal cancer cells, T 
treatment increased the concentration of 5-mC compared to 
control, while in lung cancer cells, S treatment has increased 
the global methylation of the cells.  
On the other hand, S treatment has caused the DNA global 
methylation to increase in cervical cancer cells. Furthermore, 
in the 96-hour incubation period, T treatment had elevated the 
concentration of 5-mC in breast cancer cells compared to 
control, while in colorectal cancer cells, lung cancer cells, and 
cervical cancer cells, S caused the level of global methylation 
to increase compared to control. Results were shown in Fig. 6 
and  Fig. 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The average cell count of all cells treated 
with different types of chemotherapeutic drugs. 
  
Figure 4: Mitochondrial reductase enzyme activity as 
measured by after treating the malignant cells with different 
types of chemotherapeutic drugs for 48 h. A: breast cancer 
cells, B: colon cancer, C cells lung cancer cells, and D: 
cervical cancer cells. CY: Cyclophosphamide, C: carboplatin, 
S: Sodium phenylbutyrate, and T: Temozolomide. ns: Non-
significant differences, *: significant, and **: very significant.  
 
Figure 5: Mitochondrial reductase enzyme activity as 
measured by after treating the malignant cells with 
different types of chemotherapeutic drugs for 96 h. A: 
breast cancer cells, B: colon cancer, C cells lung cancer 
cells, and D: cervical cancer cells. CY: Cyclophosphamide, 
C: carboplatin, S: Sodium phenylbutyrate, and T: 
Temozolomide. ns: Non-significant differences, *: 
significant, and **: very significant.  
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DISCUSSION: 
Cell count after treatment  
It has been indicated earlier that treating malignant cancer 
cells with epigenetic drugs causes cell proliferation to 
decrease [2, 35]. In the present study, breast, colorectal, 
lung, and cervical cancer cells were treated with different 
types of chemotherapeutic drugs, and the obtained results 
indicated that for the 48-h incubation period, PBA was the 
most effecting drug in reducing the cell count in breast, 
colorectal, and lung cancer cells. Low concentrations (15 
mmol/L) of PBA inhibited cell growth and proliferation 
mainly by causing prominent changes in cell morphology 
and promoting S- and G2/M-dependent cell cycle arrest [31, 
36]. Temozolomide was the drug the affected the cell growth 
severely, when compared to control. This profile was 
obtained in several studies [37-41]. In the second incubation 
period, PBA was the efficient drug in reducing cell 
proliferation of breast cancer cells [42], while in colorectal 
cancer cells carboplatin decreased the cell count compared 
to control [43]. Temozolomide also has negatively affected 
the lung cancer cell proliferation [44]. In cervical cancer 
cells, the overall growth of treated cells was higher than that 
of control cells, and this might be due to the cytostatic effect 
of the studied drugs on cervical cancer cells when exposed 
to long periods (96 h.) [45].  
 
Cell viability assay 
MTT was performed to assess the overall cell viability 
through measuring the mitochondrial reductase activity in 
the cells treated with different types of 
chemotherapeutic/epigenetic drugs [46]. Results obtained 
indicated almost the same profile of cell proliferation with 
exceptions, where all the drugs have caused the cell viability 
to increase in comparison to control cells. This profile was 
obtained in breast, colorectal, lung, and cervical cancer cells 
[47, 48].  
 
Global methylation quantification  
The quantification of global DNA methylation was used to 
underlie the effects of treating malignant cells with different 
types of epigenetic drugs [49-51]. Here, data obtained 
showed that in the first incubation period (48 h) 
cyclophosphamide was found to hypomethylate breast and 
cervical cancer cells [26, 52], while carboplatin was found 
to hypomethylate colon and lung cancer cells [43, 53]. PBA 
was found to increase the methylation levels in lung and 
cervical cancer cells [42], while breast cancer cells and colon 
cancer cells were hypermethylated after being treated with 
carboplatin and temozolomide, respectively [39]. In the 
second incubation period (96 h.) PBA has caused a 
significant hypermethylation in colon [28], lung [54], and 
cervical cancer cells [42], while temozolomide has elevated 
the global methylation level in breast cancer cells [37, 55, 
56]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: DNA global methylation assay after treatment of 
malignant cells by the chemotherapeutic drugs for 48 hours. 
A: breast cancer cells, B: colon cancer, C cells lung cancer 
cells, and D: cervical cancer cells. CY: Cyclophosphamide, 
C: carboplatin, S: Sodium phenylbutyrate, and T: 
Temozolomide. ns: Non-significant differences, *: 
significant, and **: very significant.  
 
Figure 7: DNA global methylation assay after treatment of 
malignant cells by the chemotherapeutic drugs for 96 
hours. A: breast cancer cells, B: colon cancer, C cells lung 
cancer cells, and D: cervical cancer cells. CY: 
Cyclophosphamide, C: carboplatin, S: Sodium 
phenylbutyrate, and T: Temozolomide. ns: Non-significant 
differences, *: significant, and **: very significant.  
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CONCLUSIONS: 
In the present study, the role of different types of 
chemotherapeutic/epigenetic drugs in modulating the 
methylome of breast, colorectal, lung, and cervical cancer 
cells was assessed. Cells were treated with a final 
concentration of 5 µm of each drug for 48 and 96 h before 
assigning the changes. Data obtained indicated that 
temozolomide, carboplatin, PBA, and cyclophosphamide 
were able to change the methylation patterns of the studies 
cells. We can conclude that using a combination of PBA and 
carboplatin could be useful in controlling malignant cell 
proliferation in vitro. 
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